Efficacy and tolerability of agomelatine in the treatment of depression

References

• OlesenJGustavssonASvenssonMWittchenHUJönssonBCDBE2010 study groupThe economic cost of brain disorders in EuropeEur J Neurol201219115516222175760
   PubMed Web of Science ®Google Scholar
• KesslerRCAguilar-GaxiolaSAlonsoJThe global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveysEpidemiol Psychiatr Soc20091812333
   PubMed Web of Science ®Google Scholar
• HickieIIs depression overdiagnosed? NoBMJ200733532917703041
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA)Practice Guideline for the Treatment of Patients with Major Depressive Disorder3rd edArlington, VAAPA2010
   Google Scholar
• National Institute for Health and Care Excellence (NICE) [webpage on the Internet]Depression: the treatment and management of depression in adults (update). NICE clinical guideline 90NICE2009 [updated February 6, 2014]. Available at: http://www.nice.org.uk/CG90Accessed February 18, 2014
   Google Scholar
• KennedySHRizviSJAgomelatine in the treatment of major depressive disorder. Potential for clinical effectivenessCNS Drugs201024647949920192279
   PubMed Web of Science ®Google Scholar
• KennedySHEisfeldBSMeyerJHBagbyRMAntidepressants in clinical practice: limitations of assessment methods and drug responseHum Psychopharmacol200116110511412404605
   PubMed Web of Science ®Google Scholar
• MannJJThe medical management of depressionN Engl J Med2005353171819183416251538
   PubMed Web of Science ®Google Scholar
• HickieIBRogersNLNovel melatonin-based therapies: potential advances in the treatment of major depressionLancet2011378979162163121596429
   PubMed Web of Science ®Google Scholar
• WilsonSArgyropoulosSAntidepressants and sleep: a qualitative review of the literatureDrugs200565792794715892588
   PubMed Web of Science ®Google Scholar
• LaderMLimitation of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic targetEur Neuropsychopharmacol20071774375517624740
   PubMed Web of Science ®Google Scholar
• EtainBMilhietVBellvierFLeboyerMGenetics of circadian rhythms and mood spectrum disordersEur Neuropsychopharmacol201121676682
   PubMed Web of Science ®Google Scholar
• TakahashiJSHongHKKoCHMcDearmonELThe genetics of mammalian circadian order and disorder: implications for physiology and diseaseNat Rev Genet2008976477518802415
   PubMed Web of Science ®Google Scholar
• RacagniGRivaMAPopoliMThe interaction between the internal clock and antidepressant efficacyInt Clin Psychopharmacol200722Suppl 2S9S1417917564
   PubMed Web of Science ®Google Scholar
• KennawayDJClock genes at the heart of depressionJ Psychopharmacol201024Suppl 851420663803
   PubMed Web of Science ®Google Scholar
• ScottJClinical parameters of circadian rhythms in affective disordersEur Neuropsychopharmacol201121671675
   Web of Science ®Google Scholar
• De BodinatCGuardiola-LemaitreBMocaërERenardPMuňozCMillanMJAgomelatine, the first melatonergic antidepressant: discovery, characterization and developmentNat Rev Drug Discov20109862864220577266
   PubMed Web of Science ®Google Scholar
• McClungCACircadian rhythms and mood regulation: insights from pre-clinical modelsEur Neuropsychopharmacol201121Suppl 4S683S69321835596
   PubMed Web of Science ®Google Scholar
• CourtetPOlieECircadian dimension and severity of depressionEur Neuropsychopharmacol201222Suppl 3S467S481
   Google Scholar
• FavaMDaytime sleepiness and insomnia as correlates of depressionJ Clin Psychiatry200465Suppl 16273215575802
   PubMed Web of Science ®Google Scholar
• AlmeidaOPPfaffJJSleep complaints among older general practice patients: association with depressionBr J Gen Pract20055552086486616282003
   PubMed Web of Science ®Google Scholar
• ShafferyJHoffmannRArmitageRThe neurobiology of depression: perspectives from animal and human sleep studiesNeuroscientist200391829812580343
   PubMed Web of Science ®Google Scholar
• TsunoNBessetARitchieKSleep and depressionJ Clin Psychiatry200566101254126916259539
   PubMed Web of Science ®Google Scholar
• DijkDJCzeislerCAContribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humansJ Neurosci1995155 Pt 1352635387751928
   PubMed Web of Science ®Google Scholar
• HickieIDavenportTA behavioural approach based on reconstructing the sleep-wake cycleCogn Behav Pract19996442450
   Google Scholar
• SwartzHAMaihoeferCCFrankEImplementing interpersonal and social rhythm therapy for mood disorders across a continuum of carePsychiatric Serv2011621113771380
   Web of Science ®Google Scholar
• DuffyJFCzeislerCAEffects of light on human circadian physiologySleep Med Clin20094216517720161220
   PubMedGoogle Scholar
• Wirz-JusticeADiurnal variations of depressive symptomsDialogues Clin Neurosci200810333734318979947
   PubMedGoogle Scholar
• WuJCKelsoeJRSchachatCRapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorderBiol Psychiatry200966329830119358978
   PubMed Web of Science ®Google Scholar
• DaltonEJRotondiDLevitanRDKennedySHBrownGMUse of slow-release melatonin in treatment-resistant depressionJ Psychiatry Neurosci2000251485210721684
   PubMed Web of Science ®Google Scholar
• DemyttenaereKAgomelatine: a narrative reviewEur Neuropsychopharmacol201121Suppl 4703709
   PubMed Web of Science ®Google Scholar
• StahlSMNovel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonismInt J Neuropsychopharmacol200710557557817681087
   PubMed Web of Science ®Google Scholar
• SansoneRASansoneLAAgomelatine, a novel antidepressantInn Clin Neuroscience20118111014
   Google Scholar
• PompiliMSerafiniGInnamoratiMAgomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical reviewWorld J Biol Psychiatry201314641243123530731
   PubMed Web of Science ®Google Scholar
• ManjiHKQuirozJASpornJEnhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult to-treat-depressionBiol Psychiatry200353870774212706957
   PubMed Web of Science ®Google Scholar
• PittengerCDumanRSStress, depression, and neuroplasticity: a convergence of mechanismNeuropsychopharmacology20083318810917851537
   PubMed Web of Science ®Google Scholar
• BachisAMalleiACruzMIWellsteinAMocchettiIChronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neuronsNeuropharmacology20085571114112018682257
   PubMed Web of Science ®Google Scholar
• MolteniRCalabreseFPisoniSSynergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administrationWorld J Biol Psychiatry201011214815320109111
   PubMed Web of Science ®Google Scholar
• SoumierABanasrMLortetSMechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampusNeuropsychopharmacol2009341123902403
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA) [webpage on the Internet]Valdoxan: Summary of Product Characteristic Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product-Information/human/000915/WC500046227.pdfAccessed April 16, 2014
   Google Scholar
• LooHHaleAD’HaenenHDetermination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range studyInt Clin Psychopharmacol200217523924712177586
   PubMed Web of Science ®Google Scholar
• KennedySHEmsleyRPlacebo-controlled trial of agomelatine in the treatment of major depressive disorderEur Neuropsychopharmacol20061629310016249073
   PubMed Web of Science ®Google Scholar
• OlieJPKasperSEfficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonist properties, in major depressive disorderInt J Neuropsychopharmacol200710566167317477888
   PubMed Web of Science ®Google Scholar
• StahlSMFavaMTrivediMHCaputoAShahAPostAAgomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trialJ Clin Psychiatry201071561662620361916
   PubMed Web of Science ®Google Scholar
• LemoinePGuilleminaultCAEAlvarezEImprovement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxineJ Clin Psychiatry200768111723173218052566
   PubMed Web of Science ®Google Scholar
• KennedySHRizviSFultonKRasmussenJA double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XRPsychopharmacol Bull2010433152521150843
   PubMedGoogle Scholar
• KasperSHajakGWulffCEfficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertralineJ Clin Psychiatry201071210912020193645
   PubMed Web of Science ®Google Scholar
• LauxGVIVALDI study groupThe antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDIPharmacopsychiatry201245728429122592503
   PubMed Web of Science ®Google Scholar
• KasperSCorrubleEHaleALemoinePMontgomerySAQuera-SalvaMAAntidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo controlInt Clin Psychopharmacol2013281121923023074
   PubMed Web of Science ®Google Scholar
• DemyttenaereKCorrubleEHaleAQuera-SalvaMAPicarel-BlanchotFKasperSA pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertralineCNS Spectr201318316317023472671
   PubMed Web of Science ®Google Scholar
• GoodwinGMEmsleyRRembrySRouillonFAgomelatine Study GroupAgomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo controlled trialJ Clin Psychiatry200970812281137
   Web of Science ®Google Scholar
• Quera SalvaMAVanierBLaredoJMajor depressive disorder, sleep EEG and agomelatine: an open-label studyInt J Neuropsychopharmacol200710569169617477886
   PubMed Web of Science ®Google Scholar
• MartinottiGSepedeGGambiFAgomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorderJ Clin Psychpoharmacol2012324487491
   Web of Science ®Google Scholar
• Di GiannantonioMDi IorioGGuglielmoRMajor depressive disorder, anhedonia and agomelatine: an open-label studyJ Biol Reg Hom Agents2011251109114
   PubMed Web of Science ®Google Scholar
• ThomeJPoleyPAgomelatine: an agent against anhedonia and abulia?J Neural Transm Epub1262013
   Web of Science ®Google Scholar
• StoneMLaughtenTJonesLRisk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug AdministrationBMJ2009339b288019671933
   PubMed Web of Science ®Google Scholar
• GibbonsRDHurKBhaumikDKMannJJThe relationship between antidepressant medication use and rate of suicideArch Gen Psychiatry200562216517215699293
   PubMed Web of Science ®Google Scholar
• MartinezCRietbrockSWiseLAntidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control studyBMJ2005330748838939315718538
   PubMed Web of Science ®Google Scholar
• KoestersMGuaianaGCiprianiABeckerTBarbuiCAgomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trialsBr J Psychiatry2013203317918723999482
   PubMed Web of Science ®Google Scholar
• GuaianaGGuptaSChiodoDDaviesSJHaederleKKoestersMAgomelatine versus other antidepressive agents for major depressionCochrane Database Syst Rev201312CD00885124343836
   PubMed Web of Science ®Google Scholar
• MonteyoAMajadasSRizviSJKennedySHThe effects of agomelatine on sexual function in depressed patients and healthy volunteersHum Psychopharmacol201126853754222102540
   PubMed Web of Science ®Google Scholar
• VoicanCSCorrubleLNaveauSPerlemuterGAntidepresasant-induced liver injury: a review for cliniciansAm J Psychiatry Epub12202013
   Web of Science ®Google Scholar
• GahrMFreudenmannRWConnemannBJHiemkeCSchönfeldt-LecuonaCAgomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactionsPharmacopsychiatry201346621422023966266
   PubMed Web of Science ®Google Scholar